Brugós, LászlóHandke, Tobias2022-11-072022-11-072022-08-22https://hdl.handle.net/2437/338980This Thesis analyses the effect of add-on mepolizumab therapy compared to the traditional therapy plan for patients with severe eosinophilic asthma bronchiale. Mepolizumab is an Anti-Interleukin 5 (Anti IL-5) Antibody. From the Department of Pulmonology, University of Debrecen, 13 patients were investigated. Eosinophil cell count, tiffeneau index (FEV1%), Quality-of-Life as well as oral corticosteroid requirement and number of acute exacerbations were compared. Mepolizumab showed significant benefits compared to traditional therapy alone.31enAsthma BronchialeMepolizumabBiologic TherapyLungPulmonologyClinical benefits of mepolizumab in the therapy of severe eosinophilic asthma bronchialeDEENK Témalista::Orvostudomány::Belgyógyászat